Clinical Trials Browser

Phase 1/2 × Neoplasm Metastasis × NET × Clear all

Neoplasm Metastasis, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

NCT04579757 2025-05-08

Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors

EndocrineGastrointestinalHead & NeckNETSarcomaThoracic

Neoplasm Metastasis, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Neuroendocrine Tumors, Small Cell Lung Carcinoma, Thyroid Carcinoma, Anaplastic

NCT03475953 2023-03-03

REGOMUNE

Phase 1/2 Unknown

747 enrolled

BreastEndocrineGastrointestinalGenitourinaryHead & NeckNETOther solid neoplasmSarcomaThoracic

Gastro-enteropancreatic neuroendocrine tumor, Turcot syndrome, Tertiary Lymphoid Structures, Mesothelioma, Malignant, Biliary Tract Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinoma, Hepatocellular, Neoplasm Metastasis, Sarcoma, Stomach Neoplasms, Thyroid Neoplasms, Triple Negative Breast Neoplasms

NCT03881306 2020-08-20

DEBOXA for Inoperable NET Liver Metastases

Phase 1/2 Unknown

60 enrolled

EndocrineNET

Neoplasm Metastasis, Neuroendocrine Tumors

Clinical Trials

BRAVESST2

Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors

REGOMUNE

DEBOXA for Inoperable NET Liver Metastases